Harvard, Dana-Farber License Screening Platform to Acetylon (GenomeWeb News)

8 March 2010, 7:30 am

NEW YORK (Genomeweb News) – Harvard University and the Dana-Farber Cancer Institute today said that they have licensed exclusive rights to a high-throughput screening and lead optimization platform for histone deactylase (HDAC) inhibitor compounds to Acetylon Pharmaceuticals.... Read More »

More Topics from "News"

• AP executive Ascheim at a glance (AP via Yahoo! Finance)
• Solid Majority of Young Adults Concerned About Meeting Their Bills and Obligations, Harvard Poll Finds (PR Newswire via Yahoo! News)
• Photo Release -- Harvard Bioscience, Inc. Launches Its First Regenerative Medicine Product (GlobeNewswire via Yahoo! Finance)
• WBOC-TV 16, Delmarvas News Leader, FOX 21 - Delaware Lacrosse Moves Up In National Polls (WBOC Salisbury)
• Holbrooke's Harvard comments slammed in Afghanistan (McClatchy Washington Bureau)
• Jonah Hill to Star in "Moneyball" as Fit, Brainy Jock-Exec (NBC Philadelphia)
• Harvard University and Dana-Farber Cancer Institute Grant Acetylon Exclusive License to Breakthrough Discovery ... (Business Wire via Yahoo! Finance)
• University Of Chicago And Ataxia Foundation Team Up For Annual Scientific And Patient Meetings (Medical News Today)
• National News More>> (KJCT 8 Grand Junction)